ISSN: 1300-7777 E-ISSN: 1308-5263
Tendency of K562 chronic myeloid leukemia cells towards cell reprogramming [Turk J Hematol]
Turk J Hematol. Ahead of Print: TJH-34445 | DOI: 10.4274/tjh.2018.0106  

Tendency of K562 chronic myeloid leukemia cells towards cell reprogramming

Açelya Yılmazer Aktuna
Ankara Universitesi - Biomedical Engineering Gölbaşı

Cancer cell reprogramming is a potential tool to study cancer progression, disease pathology and drug sensitivity. Prior to performing cancer reprogramming studies, it is important to evaluate the stemness predisposition of cells that will be reprogrammed. Here, we performed a proof-of-concept study with chronic myeloid leukemia K562 cells in order to evaluate their tendency for cancer cell reprogramming. Expression of reprogramming factors, pluripotency markers and tumor-suppressor genes were analyzed at gene and protein level via real-time RT-PCR and flow cytometry. Human PBMCs were used as positive control and K562 cells were shown to express higher levels of most of the reprogramming factors, pluripotency markers. Expression of p53, which is one of the main regulator during iPSC generation were found to be lowed in K562 cells compared to PBMCs, whereas the other tumor-suppressor genes showed higher expression levels. This study suggested that similar to healthy human PBMCs, K526 cells could be used in cancer cell reprogramming studies. Generating iPS cells from leukemia cells could help scientists to establish CML models in vitro, better understand therapy resistance and develop novel therapeutic targets.

Keywords: induced pluripotent stem cells (iPSCs); chronic myeloid leukemia; K562; disease modeling; cell reprogramming




Corresponding Author: Açelya Yılmazer Aktuna


TOOLS
Uncorrected Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686